Pfizer’s $10 Billion Obesity Drug Deal Could Reshape Treatment for 137 Million Americans
Pfizer's $10B Metsera acquisition opens the door to next-gen obesity drugs and a market projected to reach $120B by 2033. Here's what the deal means for investors.
Read this issue
